3.08
0.17 (5.84%)
| Previous Close | 2.91 |
| Open | 3.04 |
| Volume | 9,901 |
| Avg. Volume (3M) | 25,635 |
| Market Cap | 31,596,796 |
| Price / Sales | 0.540 |
| Price / Book | 0.410 |
| 52 Weeks Range | |
| Earnings Date | 22 Aug 2024 |
| Profit Margin | -111.18% |
| Operating Margin (TTM) | -82.06% |
| Diluted EPS (TTM) | -7.86 |
| Quarterly Revenue Growth (YOY) | -7.30% |
| Total Debt/Equity (MRQ) | 15.92% |
| Current Ratio (MRQ) | 3.11 |
| Operating Cash Flow (TTM) | -144.48 M |
| Levered Free Cash Flow (TTM) | 7.71 M |
| Return on Assets (TTM) | -30.91% |
| Return on Equity (TTM) | -68.89% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Mixed |
| Diagnostics & Research (Global) | Bullish | Mixed | |
| Stock | Burning Rock Biotech Limited | Mixed | Mixed |
Stockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 1.38 |
|
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| % Held by Insiders | 0.04% |
| % Held by Institutions | 61.75% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Shen Neil Nanpeng | 30 Jun 2024 | 885 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 10 Oct 2024 | Announcement | NMPA Grants Marketing Approval to the First Co-Developed NGS-Based Companion Diagnostic for Lung Cancer in China |
| 27 Sep 2024 | Announcement | Burning Rock Announces Changes to Management and Board of Directors |
| 22 Aug 2024 | Announcement | Burning Rock Reports Second Quarter 2024 Financial Results |
| 19 Aug 2024 | Announcement | Burning Rock Biotech Limited Announces Expected Delisting of American Depositary Shares |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |